fistula-needles

Register to receive a free US Market Report Suite for Dialysis Device and Concentrates report synopsis and brochure

According to a new series of reports on the U.S. market for dialysis devices and concentrates by iData Research, the industry has been slow to transition away from in-center hemodialysis treatments. The reassurance and safety of having trained professionals available has been a strong incentive for patients to choose in-center treatments. Additionally, despite the increasing number of patients requiring dialysis, many are not eligible for at-home treatment options.

The Centers for Medicare and Medicaid Services (CMS) announced a plan to cut funding for dialysis treatments by 9.4%, or approximately $970 million. These decreases in reimbursement have had a significant impact on the markets for dialysis equipment. These reductions to reimbursement limit the growth of dialysis device and concentrate markets overall.

While all types of dialysis are still growing in numbers, the market share increase per new patient is the lowest for in-center hemodialysis. The AV fistula and AV fistula needle market are the fastest growing markets as the Fistula First Breakthrough Initiative gains more traction and more medical professionals recommend AV fistulae during hemodialysis initiation for improved results and increased patient safety.

“The main driver for growth of the dialysis device equipment market will be the ever expanding demographic of Americans suffering from end-stage renal disease (ESRD),” explains Dr. Kamran Zamanian, CEO of iData. “As more patients shift to alternative methods of treatment, they help fuel growth of the market.”

The dialysis concentrates market is expected to increase since every dialysis patients uses a great deal of concentrates over the course of a year. As a result, each new patient has a positive multiplier effect on the demand for dialysis concentrates, which will serve to grow the market through 2023. The market will continue to trend toward the use of dry concentrates, which are much easier to ship and less expensive per gallon.

Fresenius, DaVita and U.S. Renal Care are the industry leaders for the provision of dialysis services within the United States. However, Fresenius is the only manufacturer that owns and operates their own clinics utilizing their own equipment and supplies. This has afforded Fresenius an exceptional lead in the U.S. dialysis market. Fresenius offers products in five of the eleven market segments including dialysis machines, dialysis concentrates, dialyzers, AV fistula needles, hemodialysis bloodlines and tubing sets.

Baxter Healthcare is the second leading competitor in the U.S. dialysis market. Baxter offers products in the same segments as Fresenius due to their acquisition of Gambro AG in September 2013 which fueled the company’s market share and greatly strengthened their stance in the U.S. and global dialysis market. Baxter is also a distributor of Rockwell medical’s dialysis concentrates. Additional competitors in the dialysis device market include Medivators, Mar Cor, B. Braun, Medcomp, Medisystems and Teleflex Medical among others.

For Further Information
More on the dialysis device market in the U.S. can be found in a series of reports published by iData Research entitled the US Market Report Suite for Dialysis Devices and Concentrates.